Clinical trials: Stage IV, NSCLC
First Line Non-Small Cell Lung Cancer
Avelumab in First-line NSCLC (JAVELIN Lung 100)
The purpose of this study was to demonstrate superiority with regard to Overall Survival (OS) or Progression Free Survival (PFS) of avelumab versus platinum-based doublet, based on an Independent Review Committee assessment, in…
- Trial name
- NCT02576574
- Testing
- Avelumab, Pemetrexed, Paclitaxel
- Where
- 349 sites in United States, Australia and 40 more
- Volunteers
- 1,214 people
- Sponsor
- EMD Serono Research & Development Institute, Inc.
Non-small Cell Lung Cancer
ctDNA as a Biomarker for Treatment in Advanced NSCLC
The dynamic monitoring of circulating tumor DNA aims to evaluate the response and progression-free survival of short-course chemotherapy (2 cycles) combined with immunotherapy in patients with locally advanced unresectable or…
- Trial name
- NCT05486988
- Testing
- Immunotherapy, Chemotherapeutic Agent, Chemotherapy
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Fuzhou General Hospital
Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic
Metformin and Carbohydrate Restriction With Platinum Based Chemotherapy In Stage IIIB/IV Non-Squamous Non-Small Cell Lung Cancer (NS-NSCLC)
Metformin is thought to activate AMP-activated protein kinase (AMPK), a major sensor of cellular energy levels and a key enzyme limiting cellular growth during times of cellular stress.
- Conditions
- Non-small Cell Lung Cancer Stage IIIB/IV, Non-small Cell Lung Cancer Metastatic, Nonsquamous Nonsmall Cell Neoplasm of Lung
- Trial name
- METRO (NCT02019979)
- Testing
- metformin, carbohydrate restricted diet
- Where
- 4 sites in United States
- Volunteers
- 14 people
- Sponsor
- Beth Israel Medical Center
Stage IV Non-Small Cell Lung Cancer
Radical RADiotherapy and Immunotherapy for Metastatic CAncer of the Lung (RRADICAL)
This phase II trial studies how well radical-dose image guided radiation therapy works in treating patients with non-small cell lung cancer that has spread to other places in the body who are undergoing immunotherapy.
- Trial name
- NCT03176173
- Testing
- Image-guided Radiation Therapy, Immunotherapy (physician's choice for standard of care immunotherapy)
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- Stanford University
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Study of Talabostat and Pemetrexed vs. Pemetrexed in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) After Failure of Platinum-Based Chemotherapy
This Phase 3 study will compare the efficacy of talabostat plus pemetrexed to pemetrexed plus placebo in patients with Stage IIIB/IV NSCLC who have failed a platinum-based chemotherapy regimen.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Lung Cancer, Neoplasms, Lung, Neoplasms, Pulmonary
- Trial name
- NCT00290017
- Testing
- talabostat, pemetrexed
- Where
- 101 sites in United States
- Volunteers
- 400 people
- Sponsor
- Point Therapeutics
Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma
EMB-01 in Combination With Osimertinib in Patients With EGFR Mutant Lung Cancer
This phase Ib/II trial studies the side effects and best dose of EMB-01 when given together with osimertinib in patients with EGFR-mutant non-small cell lung cancer that has spread to other places in the body (advanced or…
- Conditions
- Metastatic Lung Non-Small Cell Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8
- Trial name
- NCT05498389
- Testing
- EMB-01, Osimertinib
- Where
- 3 sites in United States, China
- Volunteers
- 115 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Carcinoma, Non-Small-Cell Lung
A Phase 2 Study in Patients With Advanced Non-Small Cell Lung Cancer Using New Agents With and Without Docetaxel.
To determine the effectiveness of CP-868,596 + docetaxel, AG-013736 + docetaxel and CP-868,596 + AG-013736 + docetaxel in patients previously treated for non-small cell lung cancer.
- Trial name
- NCT00386555
- Testing
- docetaxel, CP-868,596 + docetaxel, AG-013736 + docetaxel
- Sponsor
- Arog Pharmaceuticals, Inc.
Platinum Resistant Ovarian Cancer, Non Small Cell Lung Cancer Metastatic
First-in-Human Dose Escalation Study of XMT-1536 in Cancers Likely to Express NaPi2b
First-in-human, Phase 1b/2 safety study of the antibody-drug conjugate (ADC) XMT-1536 (upifitamab rilsodotin) administered as an intravenous infusion once every four weeks.
- Trial name
- NCT06517433
- Testing
- upifitamab rilsodotin
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Mersana Therapeutics
Non Small Cell Lung Cancer
A Study in Non Small Cell Lung Cancer
LY2603618 is a selective inhibitor of the deoxyribonucleic acid (DNA) damage checkpoint kinase 1 (CHK1). It was being developed as a chemotherapeutic-enhancing agent in the treatment of cancer.
- Trial name
- NCT01139775
- Testing
- Pemetrexed, Cisplatin, LY2603618
- Where
- 24 sites in Germany, Spain
- Volunteers
- 76 people
- Sponsor
- Eli Lilly and Company
Non-small Cell Lung Cancer
Efficacy and Safety Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (MK-7902/E7080) in Adults With Programmed Cell Death-Ligand 1 (PD-L1)-Positive Treatment-naïve Nonsmall Cell Lung Cancer (NSCLC) [MK-7902-007/E7080-G000-314/LEAP-007] - China Extension Study
The purpose of this study is to assess the safety and efficacy of pembrolizumab (MK-3475) combined with lenvatinib (MK-7902/E7080) compared to pembrolizumab alone (with placebo for lenvatinib) in treatment-naïve adults with no…
- Trial name
- LEAP-007 (NCT04676412)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- 17 sites in China
- Volunteers
- 107 people
- Sponsor
- Merck Sharp & Dohme LLC
Lung Cancer
Bevacizumab, Docetaxel, and Gemcitabine Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread.
- Trial name
- NCT00970684
- Testing
- bevacizumab, docetaxel, gemcitabine hydrochloride
- Where
- 4 sites in United States
- Volunteers
- 13 people
- Sponsor
- Nathan Pennell, MD, PhD
Carcinoma, Non-Small-Cell Lung, Lung Cancer
Dose Escalating Study With BAY43-9006 With Carboplatin, Paclitaxel and Bevacizumab in Untreated Stage IIIb Non-small Cell Lung Cancer (NSCLC)
To determine the tolerability, maximum tolerated dose and pharmacokinetics of this drug.
- Trial name
- NCT01069328
- Testing
- Nexavar (Sorafenib, BAY43-9006), Bevacizumab, Paclitaxel
- Where
- 2 sites in United States
- Volunteers
- 33 people
- Sponsor
- Bayer
Non-small Cell Lung Cancer
A Study of SHR-A2009 Combined With Aumolertinib Versus Aumolertinib for First-line Treatment in EGFR-mutated, Advanced or Metastatic NSCLC
This study is a randomized, controlled, open-label, multicenter Phase III clinical trial designed to compare the efficacy and safety of SHR-A2009 combined with aumolertinib versus aumolertinib monotherapy in treatment-naïve…
- Trial name
- NCT07183189
- Testing
- SHR-A2009 ; Aumolertinib, Aumolertinib
- Where
- China
- Volunteers
- 582 people
- Sponsor
- Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Lung Cancer, Metastatic Cancer
Zoledronic Acid and Positron Emission Tomography in Treating Patients With Advanced Non-Small Cell Lung Cancer
RATIONALE: A positron emission tomography scan is a procedure in which a small amount of radioactive sugar is injected into a vein, and a scanner is used to make detailed, computerized pictures of areas inside the body where…
- Trial name
- NCT00559897
- Testing
- 3'-deoxy-3'-[18F]FLT, Single photon emission computed tomography
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Barbara Ann Karmanos Cancer Institute
Lung Cancer
Specialized Radiation Therapy in Treating Patients With Stage II, Stage III, Stage IV, or Recurrent Non-Small Cell Lung Cancer and Poor Performance Status
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00986297
- Testing
- hypofractionated radiation therapy
- Where
- 2 sites in United States
- Volunteers
- 60 people
- Sponsor
- University of Texas Southwestern Medical Center
Non-Squamous Non-Small Cell Lung Cancer
A Study of Erlotinib [Tarceva] as Monotherapy or Intermittent Dosing With Docetaxel in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer. (TALISMAN)
This randomized parallel group study will assess the efficacy and safety of erlotinib [Tarceva], as monotherapy or intermittent dosing with docetaxel, in second-line setting in former-smoker male patients with advanced or…
- Trial name
- NCT01204697
- Testing
- docetaxel, erlotinib [Tarceva]
- Where
- 20 sites in Italy
- Volunteers
- 74 people
- Sponsor
- Hoffmann-La Roche
Non-small Cell Lung Cancer
Erlotinib Versus Gemcitabine/Carboplatin in Chemo-naive Stage IIIB/IV Non-Small Cell Lung Cancer Patients With Epidermal Growth Factor Receptor (EGFR) Exon 19 or 21 Mutation
Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) such as erlotinib have proved effective in second or third line therapy for advanced non-small cell lung cancer(NSCLC).It is well tolerated without the side…
- Trial name
- ML20981 (NCT00874419)
- Testing
- erlotinib, gemcitabine/carboplatin
- Where
- China
- Volunteers
- 165 people
- Sponsor
- Tongji University
Carcinoma, Non-Small-Cell Lung
A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
The primary purpose of the study is to assess how well amivantamab in combination with lazertinib or in combination with chemotherapy works (antitumor activity) in participants with epidermal growth factor receptor mutated…
- Trial name
- COPERNICUS (NCT06667076)
- Testing
- Amivantamab, Lazertinib, Chemotherapy: Pemetrexed
- Where
- 205 sites in United States, Belgium and 12 more
- Volunteers
- 480 people
- Sponsor
- Janssen Research & Development, LLC
Non-small Cell Lung Cancer
An Autologous NK/CIK Cell Product (PB101) in Combination With EGFR-TKI for Treating Lung Cancer
This study was designed to determine the safety and tolerability of PB101 (autologous NK cell product) in combination with standard of care EGFR-TKI in patients with EGFR-mutated advanced non-small cell lung cancer.
- Trial name
- NCT07271446
- Testing
- PB101 plus EGFR-TKI including gefitinib, erlotinib, afatinib, or osimertinib
- Where
- Taiwan
- Volunteers
- 8 people
- Sponsor
- Precision Biotech Taiwan Corp.
Non-small Cell Lung Cancer
A Study of DZD9008 Versus Platinum-Based Doublet Chemotherapy in Local Advanced or Metastatic Non-small Cell Lung Cancer (WU-KONG28)
This is a phase 3, open-label, randomized, multi-center study assessing the efficacy and safety of DZD9008 versus platinum-based doublet chemotherapy in participants with locally advanced or metastatic NSCLC with EGFR Exon20ins…
- Trial name
- NCT05668988
- Testing
- sunvozertinib, Pemetrexed+carboplatin
- Where
- 154 sites in United States, Argentina and 13 more
- Volunteers
- 324 people
- Sponsor
- Dizal Pharmaceuticals
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.